Table 1.
Baseline patient characteristics
| <65 years (n = 146) |
≥65 years (n = 108) |
ALL (N = 254) |
|
|---|---|---|---|
| Sex, female | 78 (53.4) | 56 (51.9) | 134 (52.8) |
| Age, years | |||
| Mean ± standard deviation | 50.6 ± 11.1 | 71.2 ± 5.2 | 59.3 ± 13.6 |
| Median (range) | 53 (17–64) | 70 (65–87) | 62 (17–87) |
| ECOG PS | |||
| 0 | 56 (38.4) | 43 (39.8) | 99 (39.0) |
| 1 | 68 (46.6) | 46 (42.6) | 114 (44.9) |
| 2 | 15 (10.3) | 13 (12.0) | 28 (11.0) |
| 3 | 6 (4.1) | 6 (5.6) | 12 (4.7) |
| 4 | 1 (0.7) | 0 | 1 (0.4) |
| Time from diagnosis to initiation of eribulin treatment (years) (n = 238) | |||
| Mean ± standard deviation | 3.57 ± 3.59 | 4.74 ± 5.54 | 4.07 ± 4.57 |
| Median (range) | 2.28 (0.2–29.2) | 2.50 (0.3–28.8) | 2.42 (0.2–29.2) |
| Target lesion (duplicate count) | |||
| Head and neck | 6 (4.1) | 10 (9.3) | 16 (6.3) |
| Trunk | 24 (16.4) | 7 (6.5) | 31 (12.2) |
| Thoracic cavity | 32 (21.9) | 24 (22.2) | 56 (22.0) |
| Retroperitoneum and abdominal cavity | 52 (35.6) | 51 (47.2) | 103 (40.6) |
| Upper extremities | 5 (3.4) | 2 (1.9) | 7 (2.8) |
| Lower extremities | 22 (15.1) | 10 (9.3) | 32 (12.6) |
| Viscera | 43 (29.5) | 28 (25.9) | 71 (28.0) |
| Genitourinary | 3 (2.1) | 3 (2.8) | 6 (2.4) |
| Digestive | 9 (6.2) | 9 (8.3) | 18 (7.1) |
| Gynecologic | 17 (11.6) | 9 (8.3) | 26 (10.2) |
| Breast | 4 (2.7) | 0 | 4 (1.6) |
| Others | 12 (8.2) | 10 (9.3) | 22 (8.7) |
| Others | 13 (8.9) | 11 (10.2) | 24 (9.4) |
| Soft tissue sarcoma subtype | |||
| Leiomyosarcoma | 43 (29.5) | 30 (27.8) | 73 (28.7) |
| Liposarcoma | 39 (26.7) | 30 (27.8) | 69 (27.2) |
| Dedifferentiated | 19 (13.0) | 21 (19.4) | 40 (15.7) |
| Myxoid | 10 (6.8) | 2 (1.9) | 12 (4.7) |
| Well-differentiated | 5 (3.4) | 2 (1.9) | 7 (2.8) |
| Pleomorphic | 2 (1.4) | 1 (0.9) | 3 (1.2) |
| Unknown | 3 (2.1) | 4 (3.7) | 7 (2.8) |
| Undifferentiated pleomorphic sarcoma | 11 (7.5) | 8 (7.4) | 19 (7.5) |
| Angiosarcoma | 5 (3.4) | 9 (8.3) | 14 (5.5) |
| Synovial sarcoma | 11 (7.5) | 2 (1.9) | 13 (5.1) |
| Rhabdomyosarcoma | 7 (4.8) | 5 (4.6) | 12 (4.7) |
| Malignant peripheral nerve sheath tumor | 4 (2.7) | 2 (1.9) | 6 (2.4) |
| Myxofibrosarcoma | 0 | 5 (4.6) | 5 (2.0) |
| Others | 26 (17.8) | 17 (15.7) | 43 (16.9) |
| Median number of previous chemotherapies (range) (n = 251) | 2 (0–11) | 2 (0–4) | 2 (0–11) |
| Number of previous chemotherapies | |||
| 0 | 7 (4.8) | 11 (10.2) | 18 (7.1) |
| 1 | 46 (31.5) | 35 (32.4) | 81 (31.9) |
| 2 | 44 (30.1) | 29 (26.9) | 73 (28.7) |
| 3 | 24 (16.4) | 21 (19.4) | 45 (17.7) |
| 4 | 12 (8.2) | 10 (9.3) | 22 (8.7) |
| ≥ 5 | 12 (8.2) | 0 | 12 (4.7) |
| Unknown | 1 (0.7) | 2 (1.9) | 3 (1.2) |
| Major previous regimens | |||
| Doxorubicin monotherapy | 54 (37.0) | 39 (36.1) | 93 (36.6) |
| Pazopanib | 45 (30.8) | 37 (34.3) | 82 (32.3) |
| Gemcitabine + docetaxel | 43 (29.5) | 25 (23.1) | 68 (26.8) |
| Doxorubicin + ifosfamide | 43 (29.5) | 15 (13.9) | 58 (22.8) |
| Trabectedin | 28 (19.2) | 20 (18.5) | 48 (18.9) |
ECOG PS Eastern Cooperative Oncology Group Performance Status